Philips wins FDA nod for DigitalDiagnost C90 digital radiography system

Philips

Philips (NYSE:PHG) said yesterday that it won FDA 510(k) clearance for its DigitalDiagnost C90 digital radiography system.

The Amsterdam-based company said that the DigitalDiagnost C90 includes a live camera image displayed directly at the tube head to provide a clear view of the anatomical area being scanned during positioning.

The newly cleared system also incorporates Philips Eleva user interface intended to improve workflows, the company said.

“In today’s world of value-based care, healthcare organizations are investing in imaging solutions that help them achieve the quadruple aim: improved outcomes, enhanced patient experience, increased staff satisfaction and lowered cost of care delivery. With solutions like the DigitalDiagnost C90, Philips is helping radiology departments get one step closer to achieving that ambition through innovation that enables higher quality images, while keeping the patient and staff experience at the forefront,” diagnostic X-ray business leader Daan van Manen said in a press release.

Earlier this month, Philips said that it launched its new Epiq Elite ultrasound system.

The post Philips wins FDA nod for DigitalDiagnost C90 digital radiography system appeared first on MassDevice.

Royal Philips, American Heart Association join to boost cardiac arrest survival

 

CPR training (Image courtesy of American Heart Association)

Royal Philips (NYSE:PHG) and the American Heart Association have paired up to increase sudden cardiac arrest (SCA) survival rates in densely populated cities around the world. The Connected Pulse program combines education programs to increase awareness of CPR with the use of publicly-available automated external defibrillators (AEDs), and new technologies to strengthen the chances for survival until the patient reach the hospital.

The American Heart Association estimates that 70% to 80% of sudden cardiac arrests occur outside the hospital. For every minute that passes without CPR and defibrillation, the patient’s chance of survival decreases by 7% to 10%. Bystander intervention and treatment with an AED can triple the survival rate to 31.4%, a heart association study notes.

Get the full story on our sister site, Medical Design & Outsourcing.

The post Royal Philips, American Heart Association join to boost cardiac arrest survival appeared first on MassDevice.

Bone adhesive dev Launchpad Medical raises $9m | Medtech Funding Roundup

Launchpad Medical

Launchpad Medical has raised $8.5 million in a new round of equity financing, according to recently posted SEC filings.

The Lowell, Mass.-based medtech company is developing the Tetranite injectable, synthetic adhesive solution intended for bone repair.

Tetranite is bioresorbable and is designed to provide instant adhesive capabilities to treat fractured bone and to stabilize metal hardware in compromised bone, according to the company’s website.

The company is looking to raise an additional $1 million in the round, which would bring the total raised to $9.5 million.

The round was joined by 71 unnamed investors, according to the filing, with the first sale date noted on December 21.

LaunchPad Medical has not yet officially commented on the funding round or how it plans to spend funds raised.

Medtech cybersecurity firm Cynerio raises $7m

Medical device cybersecurity solution developer Cynerio has raised $7 million in a new round of funding to help support its healthcare-focused cybersecurity platform.

The round was joined by Accelmed, DRC, MTIP and other global venture capital firms, the company said.

Cynerio has developed a platform intended to analyze medical workflows in an internet of medical things ecosystem, the New York-based company said.

“Cynerio is committed to protecting the future of healthcare by focusing on its weakest link – the connected medical devices and internet of medical things. We are delivering a tailor-made, healthcare driven solution for providers to ensure patient safety and data protection while maintaining operational continuity,” CEO Leon Lerman said in a press release.

Novel imaging tech dev Decision Sciences Medical raises $7m

Medical imaging tech developer Decision Sciences Medical has raised approximately $7.2 million in a new round of debt and options financing, according to a recently posted SEC filing.

Decision Medical is developing a new imaging technology it calls Acoustic Coherent Tomography. The company is currently focusing on using the system for detecting small tumors and assessing soft-tissue musculoskeletal problems.

The imaging platform is intended for emergency room use and diagnosing trauma and underlying disease, and for real-time, intra-operative imaging, according to its website.

Money in the round came from 28 unnamed investors, with the first sale dated as having occurred on October 15, 2015, according to the filing.

The company is still seeking an additional $5 million in the round, which would bring the total raised up to approximately $12.2 million, according to the SEC filing.

Philips joins $7m round for Babyscripts

Obstretics management software platform developer Babyscripts has raised $6 million in a new round of financing joined by Philips, the company said this week.

The round was also joined by StartUp Health and NueCura Partners, the San Francisco-based company said.

Babyscripts is developing a virtual care platform intended to allow OBGYNs to remotely monitor and treat pregnant patients, the company said. The platform uses internet-connected devices for remote monitoring and is intended to automate multiple elements of care.

As part of the funding round, Babyscripts said it intends to partner with Philips’ mother/baby unit to build an extensive virtual care obstetrics and pediatrics platform.

“This funding will help us continue to acquire market share while also allowing us to focus on building even more products for patients in pregnancy. We are excited to partner with a group like Philips — this is a great validation of our vision for obstetrics: a risk based model that we’ve coined ‘precision prenatal care’,” Babyscripts CEO and co-founder Anish Sebastian said in a press release.

Conventus Ortho raises $5m

Conventus Orthopaedics has raised $5 million in a new round of debt and options financing, according to a recently posted SEC filing.

The Maple Grove, Minn.-based company is developing the  Conventus Cage implant device designed for 3D fixation and fracture repair.

The Conventus Cage is designed to allow for a “less invasive” reliable 3D fixation for treating proximal humerus, distal radius and proximal radius fractures, the company said.

Money in the round came from a single unnamed investor, with the sale noted on December 31, 2018, according to the filing. The company has not yet stated how it plans to spend funds raised in the round.

ALung raises $5m

ALung Technologies has raised $5 million in a new round of debt and options financing, according to a recently posted SEC filing.

The Pittsburgh-based company is developing the Hemolung device, an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein.

Money in the round came from 61 unnamed investors, according to the filing, with the first sale noted as having occurred on December 28, 2018.

The company is not looking for anymore funds in the round, and has not yet stated how it plans to spend the funds it has raised.

BioCardia raises $4m

BioCardia (NSDQ:BCDA) has raised $4 million in a new round of equity and options financing, according to a recently posted SEC filing,

A total of three anonymous investors participated in the round, which notes its first sale as having occurred on December 24, 2018, according to the filing.

The company is not looking to raise anymore funds in the round, and has not yet stated how it plans to spend funds raised.

Pathogen detection dev Seraph Biosciences raises $2m

Pathogen detection platform developer Seraph Biosciences has raised approximately $1.5 million in a new round of equity financing, according to a recently posted SEC filing.

The company is developing the Seraspec platform, a Raman Spectroscopy system intended to provide point-of-care pathogen detection and identification, according to the company’s website.

A total of 15 anonymous investors participated in the round, with its first sale noted on December 21, 2018. The company is looking to raise an additional approximate $2.7 million, which would bring the total raised to $4.2 million, according to the filing.

Seraph Biosciences has not yet stated how it plans to spend funds raised in the round.

CoNextions Medical raises $1m

CoNextions Medical has raised approximately $1.1 million in a new round of equity financing, according to a recently posted SEC filing.

The Salt Lake City, Utah-based company is developing technologies intended to improve tending repair procedures.

The company’s flagship product is the CoNextionsTR, an alternative to traditional suture-based tendon repair techniques. The system is composed of a stainless steel and ultra-high molecular weight polyethylene implant intended to approximate tendons between 1mm and 4mm in thickness, according to the company’s website.

The company is looking to sell an additional $166,001 in the round, which would bring the total sold up to approximately $1.3 million, according to the filing.

The round has been joined by two unnamed investors, and has a minimum investment limit of $100,000, according to the filing. The first sale in the offering is dated as having occurred on December 10, 2018.

Leviticus Cardio, Jarvik Heart win $950,000 grant

Medtech developers Leviticus Cardio and Jarvik Heart have won a $950,000 grant from the Israel-U.S. Binational Industrial Research and Development Foundation.

The Israel-based medtech firms said the grant will help support the development of an implantable wireless ventricular assist device that will use both Jarvik Heart’s pump and Leviticus Cardio’s Coplanar Energy Transfer system.

“We are very grateful to the BIRD foundation for this generous grant. It comes at a crucial development phase of our wireless VAD system after we have achieved a number of very significant milestones and look towards successful human trials,” Leviticus Cardio CEO Michael Zilbershlag said in a prepared statement.

“The goal of both Jarvik Heart and Leviticus Cardio is to change the lives of heart failure patients around the world with this unique, wireless system. These funds from the BIRD foundation will help us achieve that goal,” Jarvik Heart prez & COO Peter Hinchliffe said in a press release.

 

The post Bone adhesive dev Launchpad Medical raises $9m | Medtech Funding Roundup appeared first on MassDevice.

Philips wins CE Mark for V60 Plus high flow ventilator

Philips

Royal Philips (NYSE:PHG) said today it won CE Mark approval in the European Union for its Philips V60 Plus ventilator system.

The Netherlands-based company said that the newly cleared system features both noninvasive ventilation and high flow therapy, which allows the system to be used with changing patient conditions without having to switch devices.

The V60 is intended for early interventions into respiratory failure, Philips said, but is designed to deliver a wide range of non-invasive support for patients to lessen the challenge of weaning patients off of noninvasive ventilation.

“When treating respiratory patients in intensive and emergency care settings, it’s critical for clinicians to be able to wean efficiently or to quickly escalate care depending on their patient’s condition and specific needs. This often means complex workflows and alternating devices in time-sensitive situations. We are excited to offer a comprehensive noninvasive solution that enables quick therapy and interface transitions, so clinicians can focus on providing for their patients while spending less time setting up equipment,” Philips hospital respiratory care biz lead Jim Alwan said in a prepared statement.

Philips said that it is also seeking FDA 510(k) clearance for the system, and that it has already submitted to the agency.

“We are delighted with the high flow function of the V60 Plus. It saves us a lot of time and space as we can use the same equipment for both NIV and high flow. When you need to wean patients from NIV to HFT, it is very simple with the one device. Additionally, the cannula is high quality, easy to adjust, soft against the patient’s skin and V60 flow is much quieter than our standalone high flow system,” registered nurse Peter Lindberg of Stockholm, Sweden’s St. Goran Hospital said in a press release.

Last month, Philips said that it launched an all-in-one breast assessment solution designed for use with its Epiq and Affiniti ultrasound systems.

The post Philips wins CE Mark for V60 Plus high flow ventilator appeared first on MassDevice.

Dartmouth-Hitchcock hospitals to deploy Philips’ tele-ICU program

Philips’ eICU program combines predictive analytics, data visualization, and advanced reporting capabilities to deliver vital information to bedside caregivers. (Image courtesy of Royal Philips)

Dartmouth-Hitchcock Health (Lebanon, N.H.) has agreed to implement Royal Philips’ (NYSE: PHG) eICU program technology.  The program aims to help reduce mortality, length of stay, and ventilation days while providing care to patients wherever they are located.

Philips’ eICU is a tele-ICU program that will link specialists at the health system’s flagship hospital, Dartmouth-Hitchcock Medical Center (DHMC) in Lebanon, N.H., with the patient’s local hospital. Dartmouth-Hitchcock’s program will start with medical, surgical, and neurology intensive care units at DHMC, along with the intensive care unit at Cheshire Medical Center. The program’s tele-ICU hub will also be located at DHMC, where it will leverage Philips’ IntelliSpace eCareManager, the program’s source-agnostic software, providing clinicians with a single integrated view of patient data.

Get the full story on our sister site, Medical Design & Outsourcing.

The post Dartmouth-Hitchcock hospitals to deploy Philips’ tele-ICU program appeared first on MassDevice.

Philips board backs reappointment of CEO van Houten, CFO Bhattacharya | Personnel Moves – October 29, 2018

Philips CEO Frans van Houten

Royal Philips (NYSE:PHG) said today that its board of directors is backing the re-appointment of Frans van Houten as its president and CEO and Abhijit Bhattacharya as chief financial officer and board member.

CEO van Houten has been at the head of Philips since 2011, while Bhattacharya joined the company in 2015, Amsterdam-based Philips said.

During his time in the corner office, van Houten led the initial public offering for Philips Lighting in May 2016 and has increased R&D investments and led acquisitions including Volcano, Spectranetics, Wellcentive and VitalHealth.

Board members will officially vote on a new CEO and CFO next May at the company’s annual general meeting of shareholders.

“The supervisory board is very pleased that Frans van Houten and Abhijit Bhattacharya remain available as members of the board of management. We recommend their re-appointment in view of the fundamental progress of Philips’ transformation into a solutions-driven health technology company with an improved growth and profitability profile. We are impressed by their continuing drive to further unlock Philips’ potential to grow its market positions and expand margins, as the company aims to make the world healthier and more sustainable through innovation,” Philips supervisory board chair Jeroen van der Veer said in a press release.

 Fisher & Paykel taps York as CFO

Fisher & Paykel Healthcare (NZE:FPH) said last week that it appointed Lyndal York as its new chief financial officer, set to join the company next March.

Currently, York serves as CFO to Australian company Asaleo Care. Prior to working with Asaleo Care, York acted as Cochlear‘s(ASX:COH) head of group finance and group financial controller, serving with the company for 11 years. York has also held positions with Edwards Lifesciences (NYSE:EW), Fisher & Paykel said.

“I am looking forward to joining the Fisher & Paykel Healthcare team. The company is well respected and highly successful on the global stage and I am excited to help it continue to build its reputation for sustainable growth and innovation,” York said in a press release.

York will replace long-time CFO Tony Barclay, who retired in May. Andrea Blackie will remain as acting CFO until York joins next year, the company said.

“We are delighted to welcome Lyndal to the Fisher & Paykel Healthcare team. Lyndal has strong international experience within the medical device industry, and as such, possesses a good understanding of its unique characteristics. We have a high performing and aspirational team in place and are very much looking forward to Lyndal joining us next year. I would also like to acknowledge Andrea Blackie, who has been performing the role of acting chief financial officer since 1 June 2018,” CEO & managing director Lewis Gradon said in a prepared statement.

Read more

 Harvard Biosciences names Unninayar as CFO

Harvard Biosciences (NSDQ:HBIO) said last week it named Kam Unninayar as its new CFO, effective November 26, replacing Robert Gagnon who resigned on August 31.

Prior to joining Holliston, Mass.-based Harvard Biosciences, Unninayar served as CFO at clinical stage biopharmaceutical company Tetraphase. Unninayar also spent 11 years at Thermo Fisher Scientific, holding positions as finance VP for the customer channels group, laboratory products and services division and other businesses.

“Maintaining a competitive position within the global laboratory instrumentation industry requires insightful and experienced financial management. Kam Unninayar has proven herself to be an outstanding individual in this regard with a distinguished track record. Kam brings her deep knowledge of our industry, including overseeing growth strategies, operational excellence, and acquisitions while in financial leadership positions for various business segments at public companies. I look forward to partnering with Kam as we advance the company through the next phase of growth and profitability,” Barvard Bioscience CEO Jeff Duchemin said in a prepared statement.

“Harvard Bioscience has brought life science innovations to market for more than a century. I am excited to be joining during what is a transformative phase in the company’s evolution. I look forward to being a member of the executive team to help the company deliver on its strategy, accelerate its growth trajectory, and enhance value for customers and shareholders,” Unninayar said in a press release.

Read more

 RenovaCare appoints Yan-Klassen as CFO

RenovaCare (OTC:RCAR) said last Friday that it appointed Steve Yan-Klassen as its new chief financial officer.

Prior to joining RenovaCare, Yan-Klassen has held positions with a number of accounting firms, including 5 years at BDO Canada LLP, the Scottsdale, Ariz.-based company said.

“We’re thrilled to have Steve join our roster of experienced clinical, regulatory and bioengineering professionals who have worked so hard to advance our SkinGun technology over the years. To date, over 70 patients have been experimentally treated, with many leaving the hospital in a matter of days, avoiding painful and expensive skin graft surgery. These results, along with other important factors, are why we were able to report positive outcomes from our pre-submission meeting with the U.S. FDA,” prez Thomas Bold said in a prepared release.

Read more

 Sight Sciences taps Brown as chief medical officer

Sight Sciences said last week that it tapped Dr. Reay Brown, inventor of trabecular microbypass stenting, as its new chief medical officer.

Brown has published 90 peer reviewed articles on glaucoma and cataract surgery and has served as chair of the American Society of Cataract and Refractive Surgery’s glaucoma committee and as the glaucoma editor for EyeWorld magazine.

“We are extremely proud to add someone who I consider to be one of the true pioneers in the history of modern ophthalmology to our executive team. Dr. Brown’s vast experience both as a practicing surgeon and as a prolific product innovator aligns perfectly with our company’s core competencies and, on behalf of everyone at Sight Sciences, we could not be more thrilled about Dr. Brown joining the company and furthering our mission,” CEO Paul Badawi said in a press release.

“Dr. Brown has been a major force in the surgical glaucoma space for many years and he is uniquely capable of accelerating Sight Sciences’ mission to transform ophthalmology and optometry by addressing the underlying causes of the world’s more prevalent eye diseases. We’re looking forward to working closely with Dr. Brown to bring the OMNI Surgical System to cataract surgeons and glaucoma specialists around the world and to disrupt the dry eye market with TearCare, while keeping an eye on developing new products that address marketplace needs,” chief commercial officer Shawn O’Neil said in a prepared release.

“I am thrilled to join Sight Sciences as chief medical officer. I have known the leadership team for many years and have become intimately familiar with the company’s product portfolio as an active user of OMNI in my own practice. Having innovated and worked clinically within Schlemm’s canal for many years, I believe the OMNI System has tremendous potential given its unique ability to comprehensively target all three sources of resistance in the conventional outflow pathway using a single clear corneal incision. I look forward to making improvements to the existing product portfolio whenever possible, developing new products, assisting the clinical and commercial teams in the market with OMNI and TearCare, and contributing to the growing success of the company,” Brown said in prepared remarks.

Read more

The post Philips board backs reappointment of CEO van Houten, CFO Bhattacharya | Personnel Moves – October 29, 2018 appeared first on MassDevice.

Philips launches all-in-one breast ultrasound system

Philips

Royal Philips (NYSE:PHG) said yesterday it launched an all-in-one breast assessment solution designed for use with its Epiq and Affiniti ultrasound systems.

The newly launched solution, which has received CE Mark approval in the European Union and FDA 510(k) clearance in the US, is intended for the assessment, monitoring and treatment of breast diseases, the Amsterdam-based company said.

“Ultrasound plays an increasingly important role in breast cancer screening and assessment, helping to detect lesions that mammography alone may not find. Philips is committed to developing the tools clinicians need to deliver the best care for their patients. Our integrated ultrasound solution for breast assessment delivers high-quality imaging enhanced by anatomical intelligence for results clinicians can trust,” Philips ultrasound general imaging biz lead Jeff Cohen said in a prepared statement.

Philips said that the solution is intended to reduce total exam time and the need for room or equipment changes during exams, as well as reducing the number of appointments for patients undergoing breast exams.

“The best way to increase the survival rate from breast cancer is to detect it early. For women with dense breasts, ultrasound can be very helpful in detecting masses not easily seen on the mammogram. I have been impressed by Philips’ continued investment and innovation in developing breast assessment solutions, so that I can provide optimal care for my patients,” Dr. Marcela Böhm-Vélez of Pittsburgh, Penn.’s Weinstein Imaging Associates said in a press release.

Earlier this week, Philips said that it won FDA 510(k) clearance for its IntelliVue GuardianSoftware mobile client application, designed to allow clinicians to view patient vital signs and receive early warning scores on mobile devices.

The post Philips launches all-in-one breast ultrasound system appeared first on MassDevice.

Philips wins FDA nod for IntelliVue GuardianSoftware mobile app

Philips

Royal Philips (NYSE:PHG) said today it won FDA 510(k) clearance for its IntelliVue GuardianSoftware mobile client application, designed to allow clinicians to view patient vital signs and receive early warning scores on mobile devices.

The Amsterdam-based company said that the system is intended to move information that would normally be manually recorded in hospital medical-surgical units onto mobile devices to improve workflows and responsiveness, as the software can identify signs of potential patient deterioration before an adverse event.

The IntelliVue GuardianSoftware is designed for use with compatible devices such as wearable biosensors, Philips said.

“Patient deterioration continues to be a major concern in hospitals – one that can be further exacerbated when the right solutions aren’t in place. Clinicians need data in real-time to help them identify adverse events before they occur. Philips IntelliVue GuardianSoftware is always evolving to offer clinicians an intuitive tool to optimize efficiencies and clinical resources. With the introduction of the IGS mobile client app, clinicians can deploy resources more efficiently, and have a deeper view into their patients’ status,” Philips monitoring and analytics biz leader Felix Baader said in a press release.

Earlier this week, Philips saw its shares fall in New York and London after it reported lower-than-forecast sales and earnings figures.

The post Philips wins FDA nod for IntelliVue GuardianSoftware mobile app appeared first on MassDevice.

ASTRO 2018 Roundup: Fujifilm enters US CT market with FCT Embrace

Fujifilm

Fujifilm (TSE:4901) said this week it launched the FCT Embrace 85cm wide bore computed tomography imaging unit, touting it as the world’s first such device to hit the market.

The system launch marks the company’s first foray into the CT field, FujiFilm said. The release was announced at the American Society for Radiation Oncology annual meeting ASTRO in San Antonio, Texas.

The FCT Embrace system offers 64 and 128 slice configurations, and is intended for use in both oncology and radiology applications, the Tokyo-based company said. The system offers enhanced CT simulation and radiotherapy treatment planning capabilities, Fujifilm added.

“Fujifilm is a company of ‘firsts’ in diagnostic imaging. In 1936, we took our first steps in the development of X-ray film; and in 1983, we pioneered the first digitized radiography system in the world. Once again we are innovating with the launch of the FCT Embrace, a solution that provides the most slices ever seen on an 85cm bore system. Designed to improve radiation oncology care, this advanced solution boosts patient comfort and security by offering the widest tabletop currently available at 49cm, and accommodating bariatric patients of up to 660lbs,” COO Johann Fernando said in a press release.

 Varian Medical updates on multimodal imaging AI suite

Varian Medical (NYSE:VAR) yesterday released details on its development of an artificial intelligence-driven radiotherapy treatment suite the company is designing to incorporate multiple imaging types including magnetic resonance imaging, pulse emission tomography and computed tomography.

The Palo Alto, Calif.-based said that it is developing the suite to improve workflow for clinicians and to improve access to adaptive therapy. The system is also intended to improve communications between physician and patient, and to improve patient monitoring.

“We are creating a treatment suite that includes treatment planning, treatment delivery, and patient monitoring to fuel the next generation of radiation therapy. We are doing this through multimodality imaging available at the console in combination with next generation AI-driven auto-segmentation and treatment planning.  We will make use of state of the art treatment delivery including 17-second high-resolution kV iterative cone-beam CT imaging and our advanced multi-leaf collimator design to enable delivery arcs that require just 30-seconds,” Dr. Louis Harrison of the Moffitt Cancer Center said in a prepared statement.

“Based on input from our clinical partners around the world, having MR, PET, and CT imaging all available at the console and utilization of AI automation could transform what they can visualize and adapt. We want to create a streamlined workflow that increases patient access to adaptive therapy even in the busiest clinics,” Varian oncology systems prez Chris Toth said in a press release.

Read more

 Philips unveils radiation oncology platform

Royal Philips (NYSE:PHG) put its suite of radiation oncology and software systems on display at the ASTRO 2018 meeting.

The portfolio includes a software suite intended to integrate both CT and MR imaging systems, and “represents a significant step forward in supporting improved care, accelerated time to treatment and enhanced patient satisfaction,” according to a press release.

“Care teams are continuously seeking ways to reduce uncertainty during the radiotherapy process and more confidently and efficiently deliver targeted, personalized therapy. Spanning imaging and treatment planning, our new portfolio combines advanced imaging systems with intelligent, adaptive treatment planning software. Through strong, innovative partnerships with our customers and industry partners, Philips is designing dedicated radiation oncology solutions that enhance the work of clinicians and their patient care,” Philips radiation oncology GM Ardie Ermers said in a prepared statement.

Read more

 Varian Medical launches Bravos HDR brachytherapy system

Varian Medical this week announced the launch of its Bravos Afterloader system intended for use in high dose rate brachytherapy treatments.

The Palo Alto, Calif.-based company said that the system is designed to improve workflow efficiency and simplify treatment. The system allows the operator to position the radioactive source in the appropriate applicator following a pattern designed to create a conformal dose distribution within or on the surface of the patient’s anatomy.

“We are excited about the capabilities of Bravos and have already begun treating patients in our department. As we continue to use and learn the features in this new system, the clinical efficiencies will enable us to improve our Brachytherapy workflow,” brachytherapy physicist Vicki Currie of Norfolk & Norwich University Hospital said in a prepared release.

“After spending time in clinics around the world talking with the treatment teams, we saw the opportunity to create a system that is easy to use and creates greater efficiencies, allowing clinicians to spend more time with the patient. Bravos is a big step forward for brachytherapy treatments and we will continue to collaborate with our partners in achieving new victories against cancer,” Varian global portfolio solutions VP Ed Vertatschitsch said in a press release.

Read more

 QFix Positioning launches new Symphony system brachytherapy transfer device

QFix Positioning this week said it launched a new brachytherapy transfer device for its Symphony patient transport system.

The Avondale, Penn.-based company said its Symphony system is intended for use in setup, positioning and the transfer of patients for procedures using imaging and brachytherapy treatments.

“Symphony provides a simple way to safely improve workflow efficiencies and throughput, enabling centers to treat more patients during a typical day of treatment,” CEO & CTO Dan Coppens said in a prepared statement.

Read more

 ViewRay touts MRIdian, radiotherapy data

ViewRay (NSDQ:VRAY) this week released details from its investor and analyst meeting at ASTRO 2018 and presented highlighted clinical experiences from uses of its MRIdian Systems.

In a presentation led by Dr. Louis Harrison, the Cleveland-based company spoke of the opportunity for MRI-guided radiotherapy to be used in cancer treatment.

“With MRI-guidance and the ability to adjust dosing during treatment, physicians now have the unmatched ability to personalize and adapt radiotherapy to deliver the highest biologically effective dose to patients while sparing healthy tissue and critical organs. We believe that such an approach has significant potential to improve patient outcomes, especially in cancer than has been historically difficult to treat,” Dr. Harrison said in a press release.

In a second presentation, by Dr. Michael Steinberg of the UCLA David Geffen School of Medicine, the company focused on improved visualization available with MRI-guidance as compared to cone-beam CT.

“The integration of MRI with adaptive radiotherapy represents the next generation in radiation oncology and a potential new standard of care for treating cancer. The patient, clinical and economic benefits associated with MRI-guided radiotherapy make it highly attractive to a multitude of stakeholders,” Dr. Steinberg said in a prepared statement.

Read more

The post ASTRO 2018 Roundup: Fujifilm enters US CT market with FCT Embrace appeared first on MassDevice.

Philips acquires pulse oximetry sensor maker Xhale Assurance

Royal Philips (NYSE:PHG) said this week it acquired pulse oximetry sensor maker Xhale Assurance for an undisclosed amount.

Xhale Assurance produces a disposable pulse oximetry sensor designed to be placed on the wing of the nose to monitor heart rate and blood oxygenation under low perfusion conditions, which Amsterdam-based Philips said can be challenging with conventional fingertip sensors.

Philips said that the acquisition will differentiate its existing oxygen saturation monitoring solutions protfolio and allow it to expand into an underserved clinical segment.

“Xhale Assurance’s nasal alar sensor offers exceptional clinical capabilities and strengthens our patient monitoring offering with a next-generation pulse oximetry sensor technology. The sensor technology also offers opportunities to develop measurements of further physiologic parameters. I am excited that this will augment our ability to offer solutions that enhance patient safety, support clinical workflow, improve caregiver efficiency, and help our customers implement value-based healthcare,” Philips monitoring & analytics biz leader Felix Baader said in a press release.

Earlier this week, a report emerged suggesting Philips is looking to cut another 280 jobs from its Andover, Mass.-based facilities.

The post Philips acquires pulse oximetry sensor maker Xhale Assurance appeared first on MassDevice.